Characterization of T-cell receptor β chain mRNA expression in IFN-α-responsive chronic myelogenous leukaemia patients

被引:2
作者
Shimomura, T
Fujii, S
Ezaki, I
Osato, M
Fujimoto, K
Takatsuki, K
Yamamoto, K
Kawakita, M
机构
[1] Kumamoto Natl Hosp, Inst Clin Res, Ctr Bone Marrow Transplantat & Immunotherapy, Kumamoto 8600008, Japan
[2] Kumamoto Univ, Sch Med, Dept Internal Med 2, Kumamoto 860, Japan
[3] Kyushu Univ, Med Inst Bioregulat, Fukuoka 812, Japan
[4] Kitano Hosp, Tazuke Kofukai Med Res Inst, Osaka, Japan
[5] Univ Tokyo, Fac Med, Dept Med & Phys Therapy, Tokyo, Japan
关键词
IFN-alpha; CML; immune response; TCR repertoire; RT-PCR-SSCP;
D O I
10.1046/j.1365-2141.1999.01283.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Interferon-alpha (IFN-alpha) has shown promise in the treatment of chronic phase of chronic myelogenous leukaemia (CML). IFN-alpha has also been found to indirectly upregulate the expression of major histocompatibility (MHC) antigens, and to directly increase the activity of lymphocytes against tumour cells. To elucidate whether IFN-alpha induces anti-leukaemic activity of the autologous T cells in CML patients, we analysed the accumulation of T-cell receptor (TCR) in each V beta family using the reverse transcriptase-polymerase chain reaction (RT-PCR) followed by single-strand conformation (SSCP) analysis. We found the predominant expression of the V beta 10, 12, and 14 families in the peripheral blood (PB) of CML patients, in contrast to healthy donors. Especially in IFN-alpha-responsive patients, we observed an enhancement of the accumulation of the V beta 9 and 20 families, suggesting that T cells enhanced by IFN-alpha may react with a discrete set of antigens on the surface of malignant cells. These findings may demonstrate that CML cells possess the heterogenous antigens and the clonal expansion of V beta 9(+) and V beta 20(+) T cells may be a prognostic indicator of the immune responsiveness to IFN-alpha.
引用
收藏
页码:173 / 180
页数:8
相关论文
共 48 条
[1]  
ALIMENA G, 1988, BLOOD, V72, P642
[2]   UK MEDICAL-RESEARCH-COUNCIL RANDOMIZED, MULTICENTER TRIAL OF INTERFERON-ALPHA-N1 FOR CHRONIC MYELOID-LEUKEMIA - IMPROVED SURVIVAL IRRESPECTIVE OF CYTOGENETIC RESPONSE [J].
ALLAN, NC ;
RICHARDS, SM ;
SHEPHERD, PCA .
LANCET, 1995, 345 (8962) :1392-1397
[3]   SPECIFIC BINDING OF LEUKEMIA ONCOGENE FUSION PROTEIN-PEPTIDES TO HLA CLASS-I MOLECULES [J].
BOCCHIA, M ;
WENTWORTH, PA ;
SOUTHWOOD, S ;
SIDNEY, J ;
MCGRAW, K ;
SCHEINBERG, DA ;
SETTE, A .
BLOOD, 1995, 85 (10) :2680-2684
[4]  
CALABRETTA B, 1986, J BIOL CHEM, V261, P2628
[5]   INTERACTION OF STAPHYLOCOCCUS-AUREUS TOXIN SUPERANTIGENS WITH HUMAN T-CELLS [J].
CHOI, YW ;
KOTZIN, B ;
HERRON, L ;
CALLAHAN, J ;
MARRACK, P ;
KAPPLER, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (22) :8941-8945
[6]  
Choudhury A., 1997, Blood, V90, p198A
[7]   Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion [J].
Claret, EJ ;
Alyea, EP ;
Orsini, E ;
Pickett, CC ;
Collins, H ;
Wang, YL ;
Neuberg, D ;
Soiffer, RJ ;
Ritz, J .
JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (04) :855-866
[8]   ABNORMAL TCR V-BETA REPERTOIRE IN PATIENTS WITH CHRONIC MYELOID-LEUKEMIA [J].
COLEMAN, S ;
PERERA, P ;
FISHER, J ;
HOY, T ;
BURNETT, AK ;
LIM, SH .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 90 (02) :358-363
[9]  
CROSS NCP, 1994, LEUKEMIA, V8, P186
[10]  
ELLIS TM, 1989, J IMMUNOL, V143, P4282